EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-Her2 CAR-NK92 Cells and Their Exosomes: Generation, Characterization, and Selective Cytotoxicity Against Her2-Positive Tumor Cells

Alexandru Tîrziu, Florina Maria Bojin iD, Oana Isabella Gavriliuc iD, Roxana Maria Buzan iD, Lauriana Eunice Zbîrcea iD, Manuela Grijincu iD, Virgil Păunescu

International Journal of Molecular Sciences · 07.08.2025 · 26 (15) · 7648

DOI: 10.3390/ijms26157648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.08.2025. Verfasst von Alexandru Tîrziu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Exosomes, Killer Cells, Natural, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Planul Național de Redresare și Reziliență al României, RBC-engager for NK and T cell activation in cancer immunotherapy (REAKT), “Victor Babes” University of Medicine and Pharmacy Timisoara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-engineered NK cells are a promising approach for targeted immunotherapy in Her2-positive cancers. This study aimed to generate anti-Her2 CAR-NK92 cells, to evaluate their selective cytotoxicity against Her2-positive cancer cells, and to isolate and characterize their released exosomes. NK92 cells were electroporated with piggyBac transposon vectors encoding anti-Her2 CAR and the helper transposase. Puromycin selection was performed to enrich the transduced cells. CAR and GFP expression were assessed by flow cytometry, and exosomes were isolated and characterized in terms of protein cargo and surface protein expression. Cytotoxicity was evaluated using real-time cell analysis against Her2-positive SK-BR3 cells and Her2-negative MCF-7 cells. Electroporation did not significantly affect NK92 cell viability. Puromycin selection efficiently enriched for CAR-expressing cells, with GFP positivity reaching 99.8% and a 15-fold increase in CAR surface expression compared to wild-type cells. CAR-NK92 cells demonstrated robust, Her2-specific cytotoxicity in a E:T-dependent manner, with the greatest effect observed at a 10:1 effector-to-target ratio. Exosomes derived from CAR-NK92 cells contained CAR molecules and selectively targeted Her2-positive cells. Anti-Her2 CAR-NK92 cells and their exosomes exhibit potent and selective cytotoxicity against Her2-positive cancer cells, supporting their potential as innovative immunotherapeutic agents for solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesExosomesKiller Cells, NaturalReceptors, Chimeric AntigenCytotoxicity, ImmunologicHumansCell Line, TumorMCF-7 CellsImmunotherapy, Adoptive

Stichwörter der Autor:innen

CAR-NK cellsHer2NK92 cellschimeric antigen receptorcytotoxicityexosomesimmunotherapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, Chimeric AntigenERBB2 protein, human

Autor:innen und Institutionen

  • Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, Tudor Vladimirescu Street, No. 14, 300174 Timisoara, Romania.
  • Center for Gene and Cellular Therapies in the Treatment of Cancer Timisoara-OncoGen, Clinical Emergency County Hospital "Pius Brinzeu" Timisoara, No. 156 Liviu Rebreanu, 300723 Timisoara, Romania.
  • Immuno-Physiology and Biotechnologies Center, Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, No. 2 Eftimie Murgu Square, 300041 Timisoara, Romania.

ORCID-Profile: Florina Maria Bojin, Oana Isabella Gavriliuc, Roxana Maria Buzan, Lauriana Eunice Zbîrcea, Manuela Grijincu

Förderung

  • Planul Național de Redresare și Reziliență al României
  • RBC-engager for NK and T cell activation in cancer immunotherapy (REAKT)
  • “Victor Babes” University of Medicine and Pharmacy Timisoara

Zitieren

APA

Tîrziu, A., Bojin, F. M., Gavriliuc, O. I., Buzan, R. M., Zbîrcea, L. E., Grijincu, M., & Păunescu, V. (2025). Anti-Her2 CAR-NK92 Cells and Their Exosomes: Generation, Characterization, and Selective Cytotoxicity Against Her2-Positive Tumor Cells. International Journal of Molecular Sciences, 26(15), 7648. https://doi.org/10.3390/ijms26157648

Vancouver

Tîrziu A, Bojin FM, Gavriliuc OI, Buzan RM, Zbîrcea LE, Grijincu M, et al. Anti-Her2 CAR-NK92 Cells and Their Exosomes: Generation, Characterization, and Selective Cytotoxicity Against Her2-Positive Tumor Cells. International Journal of Molecular Sciences. 2025;26(15):7648. doi:10.3390/ijms26157648

BibTeX
@article{Trziu2025,
  author = {Tîrziu, Alexandru and Bojin, Florina Maria and Gavriliuc, Oana Isabella and Buzan, Roxana Maria and Zbîrcea, Lauriana Eunice and Grijincu, Manuela and Păunescu, Virgil},
  title = {Anti-Her2 CAR-NK92 Cells and Their Exosomes: Generation, Characterization, and Selective Cytotoxicity Against Her2-Positive Tumor Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {15},
  pages = {7648},
  doi = {10.3390/ijms26157648}
}
Kostenlos starten →